Pharmacological agents currently in clinical trials for disorders in neurogastroenterology

被引:23
作者
Camilleri, Michael [1 ]
机构
[1] Mayo Clin, Rochester, MN 55905 USA
关键词
IRRITABLE-BOWEL-SYNDROME; PLACEBO-CONTROLLED TRIAL; KAPPA-OPIOID AGONIST; GASTROESOPHAGEAL-REFLUX DISEASE; CHRONIC IDIOPATHIC CONSTIPATION; RECEPTOR ANTAGONIST RAMOSETRON; TAPENTADOL EXTENDED-RELEASE; ACID TRANSPORTER INHIBITOR; CONTROLLED PHASE-3 TRIAL; DOUBLE-BLIND;
D O I
10.1172/JCI70837
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
100103 [病原生物学]; 100218 [急诊医学];
摘要
Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in understanding the mechanisms of these disorders, through basic and translational research, and in targeting the receptors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients' symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastroparesis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain.
引用
收藏
页码:4111 / 4120
页数:10
相关论文
共 119 条
[1]
Efficacy and Safety of Tapentadol Extended Release Compared with Oxycodone Controlled Release for the Management of Moderate to Severe Chronic Pain Related to Osteoarthritis of the Knee A Randomized, Double-Blind, Placebo- and Active-Controlled Phase III Study [J].
Afilalo, Marc ;
Etropolski, Mila S. ;
Kuperwasser, Brigitte ;
Kelly, Kathy ;
Okamoto, Akiko ;
Van Hove, Ilse ;
Steup, Achim ;
Lange, Bernd ;
Rauschkolb, Christine ;
Haeussler, Juergen .
CLINICAL DRUG INVESTIGATION, 2010, 30 (08) :489-505
[2]
Anderson K, 2008, GASTROENTEROLOGY, V134, pA675
[3]
Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome [J].
Andrews, C. N. ;
Griffiths, T. A. ;
Kaufman, J. ;
Vergnolle, N. ;
Surette, M. G. ;
Rioux, K. P. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (03) :374-383
[4]
Influence of ghrelin on the gastric accommodation reflex and on meal-induced satiety in man [J].
Ang, D. ;
Nicolai, H. ;
Vos, R. ;
Mimidis, K. ;
Akyuz, F. ;
Kindt, S. ;
Vanden Berghe, P. ;
Sifrim, D. ;
Depoortere, I. ;
Peeters, T. ;
Tack, J. .
NEUROGASTROENTEROLOGY AND MOTILITY, 2009, 21 (05) :535-542
[5]
The in vivo pharmacodynamics of the novel opioid receptor antagonist, TD-1211, in models of opioid-induced gastrointestinal and CNS activity [J].
Armstrong, Scott R. ;
Campbell, Christina B. ;
Richardson, Carrie L. ;
Vickery, Ross G. ;
Tsuruda, Pamela R. ;
Long, Daniel D. ;
Hegde, Sharath S. ;
Beattie, David T. .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2013, 386 (06) :471-478
[6]
Basra S, 2013, GASTROENTEROLOGY, V144, pS160
[7]
Peripherally acting opioid antagonists in the treatment of opiate-related constipation: A systematic review [J].
Becker, Gerhild ;
Galandi, Daniel ;
Blum, Hubert E. .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2007, 34 (05) :547-565
[8]
Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans [J].
Bharucha, Adil E. ;
Ravi, Karthik ;
Zinsmeister, Alan R. .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2010, 299 (01) :G215-G219
[9]
Mechanisms of Reflux Perception in Gastroesophageal Reflux Disease: A Review [J].
Bredenoord, Albert J. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (01) :8-15
[10]
Gastric Accommodation and Emptying in Evaluation of Patients With Upper Gastrointestinal Symptoms [J].
Bredenoord, Albert J. ;
Chial, Heather J. ;
Camilleri, Michael ;
Mullan, Brian P. ;
Murray, Joseph A. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2003, 1 (04) :264-272